

Japan CRISPR-Cas9 Gene Editing Market - 2024-2033

<https://marketpublishers.com/r/J48A43521415EN.html>

Date: March 2026

Pages: 180

Price: US\$ 2,999.00 (Single User License)

ID: J48A43521415EN

Abstracts

The Japan CRISPR-Cas9 Gene Editing Market was valued at US\$ 232.3 Million in 2024 and is anticipated to reach US\$ 856.4 Million by 2033, at a CAGR of 0.156 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan CRISPR-Cas9 Gene Editing Market.

This report delivers a comprehensive overview of the Japan CRISPR-Cas9 Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan CRISPR-Cas9 Gene Editing Market. The Japan CRISPR-Cas9 Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan CRISPR-Cas9 Gene Editing Market Scope:

By Product

CRISPR-Cas9 Reagents

Instruments & Systems

Software & Platforms

By Technology

CRISPR-Cas9 Nuclease Editing

CRISPR Interference (CRISPRi)

CRISPR Activation (CRISPRa)

Base Editing

Others

By End User

Pharmaceutical & Biotechnology Companies

Academic & Government Research Institutes

Clinical Research Organizations

Contract Research Organizations (CROs)

Hospitals & Diagnostic Centers

Agricultural & Food Biotechnology Firms

By Application

Drug Discovery & Development

Functional Genomics

Gene Therapy Research

Cell Line Engineering

Disease Modeling

Agricultural Biotechnology

Diagnostics & Biomarker Development

Others

By Delivery Method

Viral Systems

Non-viral Systems

By Disease Area

Oncology

Genetic Disorders

Infectious Diseases

Cardiovascular & Metabolic Disorders

Neurological Diseases

Others

Key Players

Takeda Pharmaceutical Company Limited

DAIICHI SANKYO COMPANY, LIMITED

Thermo Fisher Scientific Inc.

Merck KGaA

Takara Bio Inc.

DH Life Sciences, LLC.

GenScript

Sumitomo Chemical Co., Ltd.

Astellas Pharma Inc.

Illumina, Inc.

Major Highlights

This report delivers a comprehensive overview of the Japan CRISPR-Cas9 Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan CRISPR-Cas9 Gene Editing Market. The Japan CRISPR-Cas9 Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions

apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

3.1. Impacting Factors

3.1.1. Drivers

3.1.1.1. Increasing investments in precision medicine and genomic research in Japan

3.1.1.2. Growing adoption of CRISPR technology in drug discovery and pharmaceutical R&D

3.1.1.3. Government and institutional funding support for advanced biotechnology innovation

3.1.2. Restraints

3.1.2.1. High cost of CRISPR technology development and implementation

3.1.2.2. Ethical concerns and strict regulatory approvals for gene editing research

3.1.3. Opportunity

3.1.3.1. Rising demand for gene therapy and personalized medicine applications

3.1.3.2. Expansion of biotech collaborations between academic institutions and pharma companies

3.1.3.3. Increasing research focus on rare genetic diseases and oncology treatments

3.1.4. Trends

3.1.4.1. Development of next-generation CRISPR technologies, such as base and prime editing

3.1.4.2. Growing integration of artificial intelligence and bioinformatics in genome editing workflows

3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter's Five Force Analysis – Japan CRISPR-Cas9 Gene Editing Market

4.2. Geopolitical & Supply Chain Exposure

4.3. Social & Patient-Centric Factors

4.4. Economic Factors

4.5. Pricing Analysis

4.6. Regulatory Analysis

4.7. Go-To-Market (GTM) Strategy

4.8. Innovation & R&D Trends

4.9. Sustainability and ESG Analysis

4.10. Healthcare & Gene Therapy Ecosystem Participants

4.11. Buyer Decision Criteria & Adoption Drivers

4.12. DMI Opinion – Strategic Outlook for the Japan CRISPR-Cas9 Gene Editing Market

5. BY PRODUCT

5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

5.1.2. Market Attractiveness Index, By Product

5.2. CRISPR-Cas9 Reagents*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

5.2.3. Cas9 Enzymes

5.2.4. Guide RNAs

5.2.5. Vectors & Plasmids

5.2.6. Buffers & Kits

5.3. Instruments & Systems

5.3.1. PCR Systems

5.3.2. Electroporators

5.3.3. Microinjection Systems

5.3.4. Flow Cytometers

5.4. Software & Platforms

5.4.1. Bioinformatics & Design Tools

5.4.2. Data Analysis Software

6. BY TECHNOLOGY

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

6.1.2. Market Attractiveness Index, By Technology

6.2. CRISPR-Cas9 Nuclease Editing*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. CRISPR Interference (CRISPRi)

6.4. CRISPR Activation (CRISPRa)

6.5. Base Editing

6.6. Others

7. BY END USER

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

7.1.2. Market Attractiveness Index, By End User

7.2. Pharmaceutical & Biotechnology Companies*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Academic & Government Research Institutes

7.4. Clinical Research Organizations

7.5. Contract Research Organizations (CROs)

7.6. Hospitals & Diagnostic Centers

7.7. Agricultural & Food Biotechnology Firms

8. BY APPLICATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.1.2. Market Attractiveness Index, By Application

8.2. Drug Discovery & Development*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

- 8.3. Functional Genomics
- 8.4. Gene Therapy Research
- 8.5. Cell Line Engineering
- 8.6. Disease Modeling
- 8.7. Agricultural Biotechnology
- 8.8. Diagnostics & Biomarker Development
- 8.9. Others

9. BY DELIVERY METHOD

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Method
 - 9.1.2. Market Attractiveness Index, By Delivery Method
- 9.2. Viral Systems*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 9.2.3. Lentiviral
 - 9.2.4. Adenoviral
- 9.3. Non-viral Systems
 - 9.3.1. Electroporation
 - 9.3.2. Lipid Nanoparticles
 - 9.3.3. Physical Methods

10. BY DISEASE AREA

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
 - 10.1.2. Market Attractiveness Index, By Disease Area
- 10.2. Oncology*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Genetic Disorders
- 10.4. Infectious Diseases
- 10.5. Cardiovascular & Metabolic Disorders
- 10.6. Neurological Diseases
- 10.7. Others

11. COMPETITIVE LANDSCAPE ANALYSIS

- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 11.4. Partner Identification Analysis
- 11.5. Investment & Funding Landscape
- 11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

12.1. Takeda Pharmaceutical Company Limited*

- 12.1.1. Company Overview
- 12.1.2. Product Portfolio
- 12.1.3. Revenue Analysis
- 12.1.4. Pricing Analysis
- 12.1.5. SWOT Analysis
- 12.1.6. Recent Developments
 - 12.1.6.1. Major Deals
 - 12.1.6.2. M&A
 - 12.1.6.3. Collaboration
 - 12.1.6.4. Acquisition
 - 12.1.6.5. Joint Ventures
 - 12.1.6.6. Innovations
- 12.1.7. Recent News
 - 12.1.7.1. Events
 - 12.1.7.2. Conferences
 - 12.1.7.3. Symposiums
 - 12.1.7.4. Webinars

12.2. DAIICHI SANKYO COMPANY, LIMITED

12.3. Thermo Fisher Scientific Inc.

12.4. Merck KGaA

12.5. Takara Bio Inc.

12.6. DH Life Sciences, LLC.

12.7. GenScript

12.8. Sumitomo Chemical Co., Ltd.

12.9. Astellas Pharma Inc.

12.10. Illumina, Inc. (LIST NOT EXHAUSTIVE)

13. JAPAN CRISPR-CAS9 GENE EDITING MARKET – RESEARCH METHODOLOGY

13.1. Research Data

13.1.1. Secondary Data

13.1.2. Primary Data

13.1.3. CAGR Analysis

13.2. Market Size Estimation Methodology

13.2.1. Bottom-Up Approach

13.2.2. Top-Down Approach

13.3. Market Breakdown & Data Triangulation

13.4. Research Assumptions

13.5. Limitations

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

I would like to order

Product name: Japan CRISPR-Cas9 Gene Editing Market - 2024-2033

Product link: <https://marketpublishers.com/r/J48A43521415EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/J48A43521415EN.html>